Sarcomas of the head and neck. Prognostic factors and treatment strategies

Cancer. 1992 Jul 1;70(1):169-77. doi: 10.1002/1097-0142(19920701)70:1<169::aid-cncr2820700127>3.0.co;2-f.

Abstract

The authors reviewed 164 cases of head and neck sarcoma from adult patients seen at the University of California, Los Angeles (UCLA), between 1955 and 1988. The median follow-up was 70 months. Multivariate analysis demonstrated that tumor grade, size, and surgical margin status were the most important independent prognostic factors. Thirty-one percent (27 of 85) of patients with high-grade lesions were free of disease versus 81% (44 of 55) with low-grade lesions at last follow-up. Sixty-seven percent (50 of 76) of patients with lesions smaller than 5 cm were free of disease versus 38% (33 of 88) with lesions larger than 5 cm. In 16 patients, low-grade lesions, measuring less than 5 cm and with negative margins histologically, were controlled with surgery alone. For the 94 patients whose primary tumors were treated at UCLA, local control was achieved in 52% (26 of 50) of patients treated with surgery alone and 90% (20 of 22) with combined therapy (surgery and radiation therapy [RT] with or without chemotherapy). Seventy-five percent (6 of 8) of patients with positive surgical margins treated with postoperative RT achieved local control versus 26% (5 of 19) of patients receiving no additional treatment. In conclusion, surgery alone appears to be adequate treatment for small, low-grade tumors and negative surgical margins. Patients with incomplete resection or high-grade tumors should receive aggressive treatment--surgery and RT.

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Combined Modality Therapy
  • Dose-Response Relationship, Radiation
  • Female
  • Fibrosarcoma / mortality
  • Fibrosarcoma / pathology
  • Fibrosarcoma / therapy
  • Head and Neck Neoplasms / mortality
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / therapy*
  • Hemangiopericytoma / mortality
  • Hemangiopericytoma / pathology
  • Hemangiopericytoma / therapy
  • Hemangiosarcoma / mortality
  • Hemangiosarcoma / pathology
  • Hemangiosarcoma / therapy
  • Humans
  • Lymphatic Metastasis
  • Male
  • Neoplasm Metastasis
  • Neurilemmoma / mortality
  • Neurilemmoma / pathology
  • Neurilemmoma / therapy
  • Neurofibroma / mortality
  • Neurofibroma / pathology
  • Neurofibroma / therapy
  • Osteosarcoma / mortality
  • Osteosarcoma / pathology
  • Osteosarcoma / therapy
  • Prognosis
  • Retrospective Studies
  • Sarcoma / mortality
  • Sarcoma / pathology
  • Sarcoma / therapy*

Substances

  • Antineoplastic Agents